Contents 3 min read
Claim and source comparison
Bacopa: memory outcomes in three human research reports, extract differences and short-term safety observations.
· Bounded source comparison; not a complete clinical review or independent medical endorsement.
Systematic review / meta-analysis
Kongkeaw et al. (2014) assessed 9 studies and reported improvements particularly in attention-speed measures in a meta-analysis of 437 eligible participants. The paper does not provide one Cohen’s d≈0.3–0.5 value for every cognitive domain.
The review included 9 studies with 518 participants in total; 437 participants were eligible for meta-analysis. The findings do not establish the same benefit across all cognitive domains or every Bacopa extract.
Source 3 · Abstract read
Human randomized controlled trial
Roodenrys et al. (2002) reported a difference in retention of new information in a three-month Bacopa trial in 76 adults aged 40–65. Learning rate, attention and verbal/visual short-term memory tests were unaffected.
This result is limited to retention of new information. Everyday-memory and anxiety questionnaires did not show the same difference; faster learning in everyone cannot be inferred.
Source 2 · Abstract read
Human randomized controlled trial
Calabrese et al. (2008) randomized 54 people aged 65 or older without signs of dementia; 48 completed the trial. A specific extract at 300 mg/day for 12 weeks was associated with improvements in delayed verbal recall and the Stroop test.
This small trial cannot be generalized to other ages, dementia treatment or all products. Divided-attention and immediate-recall measures showed no difference; individual test results are not general cognitive enhancement.
Source 4 · Full text read
Correction · 2026-11-11. Memory findings were compared with their sources. Unsupported mechanism, adverse-effect frequency and general-dose statements were removed; extract and study limitations were added.
What is Bacopa Monnieri?
Standardized Bacopa monnieri extracts improved memory measures in some 12-week trials. Dendrite and neurotransmitter mechanisms are mostly preclinical; the same benefit is not established across all cognitive domains or every product.
Mechanism of Effect
Most mechanism findings in this section come from cell or animal experiments; they do not establish the same effects or clinical benefits in humans.
Clinical Evidence
Stough et al. (2001) reported differences in some learning and memory measures in a 12-week double-blind placebo-controlled Bacopa extract study in 46 healthy adults. The paper has a 2015 erratum. Corrected formulation and quantity details could not be verified against the full text in this review, so no numeric dose is stated for this study; the finding does not establish benefit for every extract or cognitive domain.
Roodenrys et al. (2002) reported a difference in retention of new information in a three-month Bacopa trial in 76 adults aged 40–65. Learning rate, attention and verbal/visual short-term memory tests were unaffected.
This result is limited to retention of new information. Everyday-memory and anxiety questionnaires did not show the same difference; faster learning in everyone cannot be inferred.
Kongkeaw et al. (2014) assessed 9 studies and reported improvements particularly in attention-speed measures in a meta-analysis of 437 eligible participants. The paper does not provide one Cohen’s d≈0.3–0.5 value for every cognitive domain.
The review included 9 studies with 518 participants in total; 437 participants were eligible for meta-analysis. The findings do not establish the same benefit across all cognitive domains or every Bacopa extract.
Calabrese et al. (2008) randomized 54 people aged 65 or older without signs of dementia; 48 completed the trial. A specific extract at 300 mg/day for 12 weeks was associated with improvements in delayed verbal recall and the Stroop test.
This small trial cannot be generalized to other ages, dementia treatment or all products. Divided-attention and immediate-recall measures showed no difference; individual test results are not general cognitive enhancement.
Dose information and research limits
Dose information and research limits
This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.
There is insufficient clinical evidence that a particular break or cycling schedule prevents tolerance or improves efficacy and safety.
Safety and Side Effects
This small, 12-week Bacopa trial does not determine long-term safety or the safety of drug combinations. Digestive complaints were reported; the research dose is not a personal recommendation.
Related research and reading
These links show explicit editorial topic connections; they do not confirm a mechanism, efficacy or the safety of combined use. News dates refer to the source or event.
Educational guides
- Nootropic Stacks: Evidence and Risks of Five Combinations
Compare evidence and interaction risks for caffeine–L-theanine and other combinations; single-ingredient findings do not prove clinical synergy for every stack.
- Neuroplasticity: mechanisms, human evidence and research limits
The brain’s capacity to change does not establish that a supplement renews it. This guide compares synaptic mechanisms with measured human outcomes and explains what learning, exercise and product research can establish, and what remains uncertain.
- Getting Started with Nootropics: Evidence and Safety Limits
Assess product form, study population and drug interactions; beginner trios, titration and on-off schedules are not protocols established for everyone.
Sources
- Stough C, et al. (2001). The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology, 156(4), 481–484. PubMed · PMID 11498727
- Roodenrys S, et al. (2002). Chronic effects of Brahmi (Bacopa monnieri) on human memory. Neuropsychopharmacology, 27(2), 279–281. PubMed · PMID 12093601
- Kongkeaw C, et al. (2014). Meta-analysis of randomized controlled trials on cognitive effects of Bacopa monnieri extract. Journal of Ethnopharmacology, 151(1), 528–535. PubMed · PMID 24252493
- Calabrese C, et al. (2008). Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: a randomized, double-blind, placebo-controlled trial. Journal of Alternative and Complementary Medicine, 14(6), 707–713. PubMed · PMID 18611150
- Peth-Nui T, et al. (2012). Effects of 12-week Bacopa monnieri consumption on attention, cognitive processing, working memory, and functions of both cholinergic and monoaminergic systems in healthy elderly volunteers. Evidence-Based Complementary and Alternative Medicine. PubMed · PMID 23320031
Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory
Frequently Asked Questions
Standardized Bacopa monnieri extracts improved memory measures in some 12-week trials. Dendrite and neurotransmitter mechanisms are mostly preclinical; the same benefit is not established across all cognitive domains or every product.
Bacopa extracts and bacoside assay methods differ; label percentages are not directly comparable and there is no universal minimum of 45%. Taking it with food may help digestive tolerance; loss of efficacy without a fatty meal has not been clinically established.
No established timeframe
This small, 12-week Bacopa trial does not determine long-term safety or the safety of drug combinations. Digestive complaints were reported; the research dose is not a personal recommendation.
Sale and import status in Türkiye must be checked for the specific product. Verify supplement approval in the Ministry of Agriculture and Forestry GGBS list, and medicine authorization and conditions of use in TİTCK records. Online availability does not establish approval or unrestricted personal import; current Ministry of Trade conditions apply to postal and express shipments.